Today’s Trending Stocks: Sarepta, Humana, HTG Molecular Diagnostics, and More

Page 1 of 2

After yesterday’s rather sharp fall, Wall Street is quiet today as the Dow is up only 14 points while the NASDAQ is 0.01% in the green. In this article, we analyze some stocks that are more volatile than the broader market and that are capturing traders’ attention.

Let’s take a closer look at Sarepta Therapeutics Inc (NASDAQ:SRPT), Humana Inc (NYSE:HUM), Western Digital Corp (NASDAQ:WDC), Lloyds Banking Group PLC (ADR) (NYSE:LYG), and HTG Molecular Diagnostics Inc (NASDAQ:HTGM) and see what the smart money investors tracked by us think about them.

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see the details here).

Biotech Stocks 7
Sarepta Therapeutics Inc (NASDAQ:SRPT) is 1.9% in the green after various investors circulated an Anthem Inc (NYSE:ANTM) review request for Sarepta’s Exondys 51. The insurer previously dealt the drug a blow by saying that Exondys 51 is considered investigational ‘and not medically necessary for all indications, including but not limited to the treatment of Duchenne muscular dystrophy’. With this review request, investors may get more clarity on exactly what Anthem’s stance is for the drug. Steve Cohen‘s Point72 Asset Management held 2.74 million shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) at the end of June.

Follow Sarepta Therapeutics Inc. (NASDAQ:SRPT)

Humana Inc (NYSE:HUM) shares have dropped by over 5% after the Centers for Medicare and Medicaid Services published a report showing that the percentage of Humana’s July 31 membership in 4-Star plans or higher declined to around 37%, or 1.17 million members, from around 78%, or 2.15 million members, in the prior year. Humana has responded by saying that the decline does not ‘take into account certain operational actions the company intends to take over the coming quarters to mitigate any potential negative impact of these published ratings on Star bonus revenues for 2018’. Seperately, Humana management raised full-year EPS guidance to $8.80 on a GAAP basis and $9.50 on an adjusted basis. Third-quarter EPS guidance was also increased to $3.07 on a GAAP basis and $3.15 on an adjusted basis. Of the around 749 funds that we track, 64 owned shares of Humana Inc (NYSE:HUM) at the end of June, unchanged from the previous quarter.

Follow Humana Inc (NYSE:HUM)

On the next page, we find out why Western Digital Corp, Lloyds Banking Group PLC (ADR), and HTG Molecular Diagnostics Inc are trending.

Page 1 of 2